Mayne Pharma Group Limited (ASX:MYX)
Australia
· Delayed Price · Currency is AUD 7.20
+1.79 (33.09%)
Feb 21, 2025, 4:10 PM AEST
Mayne Pharma Group Revenue
In the fiscal year ending June 30, 2024, Mayne Pharma Group had annual revenue of 388.40M AUD with 111.56% growth. Mayne Pharma Group had revenue of 200.47M in the half year ending June 30, 2024, with 2,870.41% growth.
Revenue
388.40M
Revenue Growth
+111.56%
P/S Ratio
1.48
Revenue / Employee
401.65K
Employees
967
Market Cap
584.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 388.40M | 204.81M | 111.56% |
| Jun 30, 2023 | 183.59M | 26.44M | 16.82% |
| Jun 30, 2022 | 157.15M | -243.63M | -60.79% |
| Jun 30, 2021 | 400.78M | -56.20M | -12.30% |
| Jun 30, 2020 | 456.99M | -68.22M | -12.99% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Telix Pharmaceuticals | 783.21M |
| Ramsay Health Care | 16.66B |
| Ansell | 3.00B |
| Mesoblast | 8.85M |
Mayne Pharma Group News
- 12 days ago - Mayne Pharma expects earnings to triple, shares jump 24pc - The Australian Financial Review
- 3 months ago - FEDERAL CONTRACEPTION PROPOSAL TO EXPAND ACCESS AND AFFORDABLE COVERAGE PAVES A STRONGER PATH FOR MAYNE PHARMA'S GROWTH IN WOMEN'S HEALTH - PRNewsWire
- 7 months ago - Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement - Reuters
- 1 year ago - Mayne Pharma Group Limited (MAYNF) Q2 2024 Earnings Call Transcript - Seeking Alpha